| The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. | |
| | |
MedLine Citation:
|
PMID: 15054088 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Anthracycline antibiotics are potent antitumor agents whose activity is severely limited by a cumulative dose-dependent chronic cardiotoxicity that results from the summation of multiple biochemical pathways of cellular damage, which ultimately yields to disruption of myocardiocyte integrity and loss of cardiac function. Nitric oxide (NO) is a key molecule involved in the pathophysiology of heart; dysregulation of activity of NO synthases (NOSs) and of NO metabolism seems to be a common feature in various cardiac diseases. The contribution of NO to anthracycline cardiac damage is suggested by evidence demonstrating anthracycline-mediated induction of NOS expression and NO release in heart and the ability of NOSs to promote anthracycline redox cycling to produce reactive oxygen species (ROS), including O2-* and H2O2. Overproduction of ROS and NO yields to reactive nitrogen species, particularly the powerful oxidant molecule peroxynitrite (ONOO-), which may produce the marked reduction of cardiac contractility. This review focuses on the anthracycline-mediated deregulation of NO network and presents an unifying viewpoint of the main molecular mechanisms involved in the pathogenesis of anthracycline cardiotoxicity, including iron, free radicals, and novel mechanistic notions on cardiac ceramide signaling and apoptosis. The data presented in the literature encourage the development of strategies of pharmacological manipulation of NO metabolism to be used as a novel approach to the prevention of cardiotoxicity induced by anthracyclines. |
| | |
Authors:
|
Stefano Fogli; Paola Nieri; Maria Cristina Breschi |
Related Documents
:
|
3978668 - Freeze-thaw injury of rat heart across an intact diaphragm: a new model for the study o... 11106558 - Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial i... 23275278 - Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucind... 18519848 - Follistatin-like 1 is an akt-regulated cardioprotective factor that is secreted by the ... 10381988 - Hyperkalemia and ionized hypocalcemia during cardiac arrest and resuscitation: possible... 2766508 - Diagnostic value of qrst isointegral maps in detecting myocardial infarction complicate... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: FASEB journal : official publication of the Federation of American Societies for Experimental Biology Volume: 18 ISSN: 1530-6860 ISO Abbreviation: FASEB J. Publication Date: 2004 Apr |
Date Detail:
|
Created Date: 2004-03-31 Completed Date: 2004-07-15 Revised Date: 2012-02-15 |
Medline Journal Info:
|
Nlm Unique ID: 8804484 Medline TA: FASEB J Country: United States |
Other Details:
|
Languages: eng Pagination: 664-75 Citation Subset: IM |
Affiliation:
|
Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa, Via Bonanno, 6, Pisa, PI 56126 Italy. s.fogli@do.med.unipi.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anthracyclines / antagonists & inhibitors, toxicity* Anti-Bacterial Agents / toxicity* Cardiomyopathies / chemically induced*, pathology, prevention & control Models, Biological Myocardium / metabolism, pathology Nitric Oxide / physiology* |
| Chemical | |
Reg. No./Substance:
|
0/Anthracyclines; 0/Anti-Bacterial Agents; 10102-43-9/Nitric Oxide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Gene and cell-based therapies for heart disease.
Next Document: Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis.